Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study

BACKGROUND AND AIMS: There are two types of serum uric acid‐lowering agents, the xanthine oxidoreductase (XO) inhibitor and non‐XO inhibitor. We investigated whether febuxostat, XO inhibitor, could produce more favorable effects on coronary endothelial function (CEF) and renal function than benzbrom...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishino, Masami, Egami, Yasuyuki, Nakamura, Hitoshi, Ukita, Kohei, Kawamura, Akito, Matsuhiro, Yutaka, Yasumoto, Koji, Tsuda, Masaki, Tanaka, Akihiro, Okamoto, Naotaka, Matsunaga‐Lee, Yasuharu, Yano, Masamichi, Shutta, Ryu, Tanouchi, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939499/
https://www.ncbi.nlm.nih.gov/pubmed/35356803
http://dx.doi.org/10.1002/hsr2.563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939499/
https://www.ncbi.nlm.nih.gov/pubmed/35356803
http://dx.doi.org/10.1002/hsr2.563

Ejemplares similares